MEI Pharma CEO Daniel Gold's 2019 pay falls 38% to $1.9M

MEI Pharma reports 2019 executive compensation

By ExecPay News

Published: October 23, 2019

MEI Pharma reported fiscal year 2019 executive compensation information on October 23, 2019.
In 2019, four MEI Pharma executives received on average a compensation package of $1.2M, a 24% decrease compared to previous year.
Average pay of disclosed executives at MEI Pharma
Daniel P. Gold, Chief Executive Officer, received $1.9M in total, which decreased by 38% compared to 2018. 51.48% of Gold's compensation, or $954.6K, was in option awards. Gold also received $289.8K in non-equity incentive plan and $610K in salary.
David M. Urso, Chief Operating Officer, received a compensation package of $1.3M, which increased by 5% compared to previous year. 53.52% of the compensation package, or $700.1K, was in option awards.
Brian G. Drazba, Chief Financial Officer, earned $842.6K in 2019, a 17% decrease compared to previous year.
Robert D. Mass, Chief Medical Officer, received $674.3K in 2019, which decreases by 23% compared to 2018.
MEI Pharma's fiscal year ends on June 30.

Related executives

Daniel Gold

MEI Pharma

Chief Executive Officer

Brian Drazba

MEI Pharma

Chief Financial Officer

Robert Mass

MEI Pharma

Chief Medical Officer

David Urso

MEI Pharma

Chief Operating Officer

You may also like

Source: SEC filing on October 23, 2019.